However, when we divided the cohorts based on APOE4 status (a well-known AD risk factor), the APOE4 carriers in Cohort I demonstrated significantly lower IAPPO-IgA levels compared with non-carriers. This evidence concerns the gene APOE and Alzheimer disease.